The value of osteoporosis interventions: evaluating the cost-effectiveness and incorporating patients’ preference

骨质疏松症干预措施的价值：评估成本效益并纳入患者偏好

• 批准号: nhmrc : GNT1139826
• 负责人: Dr Lei Si
• 金额: $ 31.88万
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/value-osteoporosis-interventions-patients-preference/1348258
• 关键词: value; osteoporosis; interventions; evaluating; cost

Osteoporosis (OP) poses substantial disease and economic burden. Many medications are publicly available and subsidized in Australia, and many new medications are on the horizon. Their value for money, however, is questionable without solid health economic evidence. In addition, patient preference for OP treatment is not well understood. My project is to develop a global health economics model to identify cost-effective treatments, and to elicit patient preference for different OP treatments.

骨质疏松症（OP）造成了巨大的疾病和经济负担。在澳大利亚，许多药物都是公开可用的，并得到补贴，许多新药物即将问世。然而，如果没有可靠的健康经济证据，它们的物有所值就值得怀疑。此外，患者对OP治疗的偏好尚不清楚。我的项目是开发一个全球卫生经济学模型，以确定具有成本效益的治疗方法，并引发患者对不同OP治疗的偏好。